343 related articles for article (PubMed ID: 24971315)
1. Prostate cancer and bone: the elective affinities.
Rucci N; Angelucci A
Biomed Res Int; 2014; 2014():167035. PubMed ID: 24971315
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Morphometric evidence for bone resorption and replacement in prostate cancer.
Clarke NW; McClure J; George NJ
Br J Urol; 1991 Jul; 68(1):74-80. PubMed ID: 1873694
[TBL] [Abstract][Full Text] [Related]
4. Generalised increase in bone resorption in carcinoma of the prostate.
Urwin GH; Percival RC; Harris S; Beneton MN; Williams JL; Kanis JA
Br J Urol; 1985 Dec; 57(6):721-3. PubMed ID: 4084733
[TBL] [Abstract][Full Text] [Related]
5. Targeting bone physiology for the treatment of metastatic prostate cancer.
Autio KA; Morris MJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
[TBL] [Abstract][Full Text] [Related]
6. Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow.
Wang C; Wang J; Chen K; Pang H; Li X; Zhu J; Ma Y; Qiu T; Li W; Xie J; Zhang J
Cancer Sci; 2020 Oct; 111(10):3600-3612. PubMed ID: 32770813
[TBL] [Abstract][Full Text] [Related]
7. Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?
Leeming DJ; Byrjalsen I; Qvist P; Koizumi M; Lynnerup N; Fregerslev M; Sørensen MG; Christiansen C; Karsdal MA
BMC Cancer; 2008 Jun; 8():180. PubMed ID: 18588674
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
Sudhan DR; Pampo C; Rice L; Siemann DW
Int J Cancer; 2016 Jun; 138(11):2665-77. PubMed ID: 26757413
[TBL] [Abstract][Full Text] [Related]
9. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
10. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
[TBL] [Abstract][Full Text] [Related]
11. CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer.
Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR
J Pathol; 2016 Jun; 239(2):218-30. PubMed ID: 27174786
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
13. The Difficult Task of Diagnosing Prostate Cancer Metastases on Dry Bone.
Castoldi E; Cappella A; Gibelli D; Sforza C; Cattaneo C
J Forensic Sci; 2018 May; 63(3):672-682. PubMed ID: 28833112
[TBL] [Abstract][Full Text] [Related]
14. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
15. Characterization of bone metastases from rapid autopsies of prostate cancer patients.
Mehra R; Kumar-Sinha C; Shankar S; Lonigro RJ; Jing X; Philips NE; Siddiqui J; Han B; Cao X; Smith DC; Shah RB; Chinnaiyan AM; Pienta KJ
Clin Cancer Res; 2011 Jun; 17(12):3924-32. PubMed ID: 21555375
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates in prostate carcinoma.
Adami S
Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
[TBL] [Abstract][Full Text] [Related]
17. [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
Seegenschmiedt MH; Oppenkowski R
Praxis (Bern 1994); 2001 Sep; 90(38):1645-52. PubMed ID: 11675918
[TBL] [Abstract][Full Text] [Related]
18. [Pathophysiology of bone metastases in urologic carcinomas].
Sauer G; Barth TF; Möller P
Urologe A; 2007 Aug; 46(8):888-90. PubMed ID: 17632696
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.
Larson SR; Chin J; Zhang X; Brown LG; Coleman IM; Lakely B; Tenniswood M; Corey E; Nelson PS; Vessella RL; Morrissey C
Clin Exp Metastasis; 2014 Feb; 31(2):247-56. PubMed ID: 24242705
[TBL] [Abstract][Full Text] [Related]
20. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
